Pfizer Sees Unusually Large Options Volume (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) saw unusually large options trading on Tuesday. Stock investors acquired 147,173 put options on the company. This is an increase of 24% compared to the average volume of 118,483 put options.

Pfizer Trading Up 0.2%

PFE traded up $0.07 on Tuesday, hitting $28.52. 20,313,657 shares of the company were exchanged, compared to its average volume of 41,667,371. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer has a 12 month low of $23.58 and a 12 month high of $29.09. The stock has a market capitalization of $162.58 billion, a PE ratio of 37.57 and a beta of 0.34. The firm has a fifty day simple moving average of $25.62 and a two-hundred day simple moving average of $26.30.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company earned $0.78 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is currently 226.32%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. JPMorgan Chase & Co. cut their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. UBS Group reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Weiss Ratings cut shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.28.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Depo-Provera litigation settlement removes a major overhang. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging a link between its contraceptive Depo-Provera and intracranial meningioma. Although the financial terms were not disclosed and Pfizer admitted no liability, resolving the cases may reduce legal uncertainty and future litigation risk. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
• Positive Sentiment: Oncology remains a key growth opportunity. Pfizer’s cancer-drug portfolio is led by Padcev, while additional pipeline programs, including PF-08634404, and potential label expansions could support longer-term revenue growth as the company works to offset declines in older products. From Padcev to PF-08634404: Pfizer’s Oncology Growth Push
• Positive Sentiment: Higher earnings expectations and dividend appeal support the stock. Erste Group Bank increased its fiscal 2026 EPS estimate, while Pfizer’s relatively high dividend yield may attract income-focused investors seeking defensive healthcare exposure. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank Three Stocks for Investors Who Still Believe Cash Is King
• Neutral Sentiment: Unusually high put-option activity signals increased hedging or bearish speculation. Traders bought 147,173 put options, about 24% above typical volume. This indicates heightened investor caution, but options activity alone does not confirm a shift in the stock’s fundamental outlook.
• Negative Sentiment: Pfizer continues to lag the broader market. Despite moderately optimistic analyst views and a recent recovery, the stock has underperformed the S&P 500 over the past year, highlighting ongoing concerns about growth and the company’s turnaround. Is Pfizer Stock Underperforming the S&P 500?

Institutional Trading of Pfizer

A number of large investors have recently made changes to their positions in PFE. Evolution Wealth Management Inc. grew its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the period. Godfrey Financial Associates Inc. purchased a new position in Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC bought a new position in shares of Pfizer during the second quarter worth $26,000. HFM Investment Advisors LLC grew its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Field & Main Bank bought a new position in Pfizer during the second quarter valued at approximately $27,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.